Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
The cash injection is conditional on the cancellation of Sphere’s AIM shares, which shareholders are being urged to approve
Sales might have missed expectations, but a lower effective tax rate helped Medtronic to beat earnings targets
It was only a brief pre-close trading update, but there will be enough in it to please Sareum investors
A home run, by the way, is taking a promising drug candidate from the clinic onto the market
OptiBiotix said this was the “first of a number of steps” being taken to build the profile of LPLDL cholesterol-reducing strain in the US
Clinigen confirmed it had submitted an ‘indicative proposal’ – not a firm intention – regarding a possible cash-and-shares offer
Wichmann will replace current boss Stephen Hemsley, who is to take up the newly-created positon of executive chairman
Revenues were actually down in the year before, but the biomaterials and medical device IP group said the overall “quality and maintainability of sales is much better”
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now